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Objectives: Aspirin therapy is usually continued throughout the perioperative period to reduce the risk for thromboem-
bolic stroke and myocardial infarction after carotid endarterectomy (CEA). Aspirin irreversibly binds cyclooxygenase-1,
thereby reducing platelet aggregation for the lifetime of each platelet. However, recent research from this unit has shown
that aggregation in response to arachidonic acid increases significantly, but transiently, during CEA, which suggests that
the anti-platelet effect of aspirin is temporarily reversed. The purpose of the current study was to determine when this
phenomenon occurs and to identify the possible mechanisms involved.
Methods: Platelet aggregation was measured in platelet-rich plasma from 41 patients undergoing CEA who were stabilized
with 150 mg of aspirin daily. Blood was taken at 8 time points: before anesthesia, after anesthesia, before heparinization,
3 minutes after heparinization, 3 minutes after shunt insertion, 10 minutes after flow restoration, 4 hours postopera-
tively, and 24 hours postoperatively. Platelet aggregation was also measured at similar times in a group of 18 patients
undergoing peripheral angioplasty without general anesthesia.
Results: All patient platelets were effectively inhibited by aspirin at the start of the operation. There was a significant
intraoperative increase in platelet response to arachidonic acid in both groups of patients, which occurred within 3
minutes of administration of unfractionated heparin. In the CEA group this resulted in a greater than 10-fold increase
in mean aggregation, to 5 mmol/L of arachidonic acid (5 mmol/L), rising from 3.9%  2.2% preoperatively to 45.1% 
29.3% after administration of heparin (P < .0001). This increased aggregation persisted into the early postoperative
period, but by 24 hours post operation aggregation had returned to near preoperative values. Aggregation in response to
other platelet agonists (adenosine diphosphate, thrombin receptor agonist peptide) showed only a small increase at the
same time, which could be accounted for by a parallel increase in the level of spontaneous aggregation.
Conclusion: Administration of heparin significantly increases platelet aggregation in response to arachidonic acid, despite
adequate inhibition by aspirin administered preoperatively. This apparent reversal in anti-platelet activity persisted into
the immediate early postoperative period, and could explain why a small proportion of patients are at increased risk for
acute cardiovascular events after major vascular surgery, despite aspirin therapy. (J Vasc Surg 2004;40:463-8.)The benefits of carotid endarterectomy (CEA) in pre-
venting long-term stroke in patients with symptomatic
carotid artery stenosis are well recognized.1,2 Much has
been done to improve the overall safety of CEA.3,4 How-
ever, there remains a small but significant risk for perioper-
ative thromboembolic stroke5 and myocardial infarction.6
These events can occur despite administration of oral anti-
platelet agents, usually aspirin.
The main anti-platelet effect of aspirin is mediated by
irreversible inactivation of cyclooxygenase (COX)–1 activ-
ity, by acetylation of the Ser-530 residue, preventing the
conversion of arachidonic acid to the prostaglandin en-
doperoxides prostaglandin G2 and prostaglandin H2,
which are intermediate metabolites in the formation of
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Because platelets do not contain a nucleus, this inhibition
cannot be overcome by synthesis of new COX-1. We were
therefore surprised to observe, in a previous study of plate-
let function during CEA, that platelet aggregation in re-
sponse to arachidonic acid increased markedly at some
stage during the operation.8 This effect was transient, and
appears to contradict current evidence on the mechanism of
action of aspirin.
The current study was undertaken to determine the
exact time during surgery when these changes in platelet
aggregation to arachidonic acid were occurring and to gain
insight into the possible causes of this phenomenon.
METHODS
Patients. Ethical committee approval was granted,
and all patients gave written informed consent. A consecu-
tive series of patients undergoing elective CEA were stud-
ied. Forty-one patients fitted the inclusion criteria for the
study, namely, primary procedure, no known platelet or
hematologic disorder, no contraindication for aspirin ther-
apy, not taking other anti-platelet agents or anticoagulant
agents, and able to give informed consent.463
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angioplasty were also studied. These patients were chosen
because they were undergoing a procedure with similar
endothelial disruption as in CEA, but with minimal soft
tissue dissection, and under local rather than general anes-
thesia.
All patients in both groups had taken 150 mg/day of
aspirin for at least 4 weeks before surgery. Any patient who
exhibited greater than 10% aggregation to 5 mmol/L1 of
arachidonic acid preoperatively was presumed to be either
noncompliant or “aspirin resistant,” and was excluded from
the study.
CEA. All patients underwent CEA under normocar-
bic, normotensive general anaesthesia. A bolus of 5000
units of unfractionated porcine heparin of mucosal origin
(Multiparin; CP Pharmaceuticals) was given before clamp-
ing the carotid artery, and a policy of routine shunting,
completion angioscopy, and perioperative transcranial
Doppler monitoring was used in all patients to minimize
inadvertent technical error.9 No patients received prota-
mine.
Angioplasty. Lower limb angioplasty was performed
in 18 patients with symptomatic iliac or superficial femoral
artery atherosclerotic disease. These procedures were car-
ried out with local anesthesia, with iohexol contrast me-
dium (Omnipaque; Amersham), and a bolus of unfraction-
ated porcine heparin (Multiparin; 2500-3500 units,
depending on body weight) was given before the angio-
plasty procedure. No patient received protamine.
Blood collection. To test whether changes in platelet
aggregation occurred at a specific time during the CEA
procedure, blood samples were collected as follows. In the
CEA group samples were taken at 8 perioperative time
points: A, preoperatively, at admission to hospital; B, after
induction of anaesthesia but before the skin incision; C,
after skin incision and soft tissue dissection but before
administration of heparin; D, 3 minutes after administra-
tion of heparin but before shunt insertion; E, 3 minutes
after shunt opening; F, after flow restoration; G, 4 hours
postoperatively; and H, 24 hours postoperatively but be-
fore administration of the next dose of aspirin.
Blood from patients undergoing angioplasty was ana-
lyzed at 5 time points: A, pre-procedure; B, after prelimi-
nary angiography; C, 3 minutes after systemic hepariniza-
tion; D, 3 minutes after the angioplasty procedure; and E, 4
hours post procedure.
All blood samples were taken from an indwelling arte-
rial line into Vacutainer tubes (Becton Dickinson). For all
samples the first 3 mL of blood was taken into ethylenedi-
amine tetraacetic acid (5.4 mg) and used to obtain a full
blood count (ACT Diff analyser; Coulter Electronics). Sub-
sequent samples were taken into trisodium citrate (3.2%
w/v) for analysis of platelet function.
Platelet aggregometry. Platelet-rich plasma was pre-
pared for aggregometry by centrifugation of the citrated
blood for 20 minutes at 900 rpm. Born-type aggregom-
etry10 was used to assess platelet aggregation in response to
increasing concentrations of arachidonic acid (2.5 and 5mmol/L; Sigma), increasing concentrations of adenosine
diphosphate (ADP; 2.5 and 5 mol/L; Sigma), and in-
creasing concentrations of thrombin-receptor activating
peptide (TRAP; 3 and 6 mol/L; PNAC Laboratory,
University of Leicester). Spontaneous aggregation was also
tested.
In all patients aggregation was measured in a PAP4
aggregometer (BioData Corp) over 10 minutes so that
aggregation reached a maximum in all subjects. Data are
expressed as the percentage of maximal aggregation, with
use of autologous platelet-poor plasma to set the value for
100%.
Statistical analysis. Normally distributed data were
analyzed with the paired Student t test. The Mann-Whitney
U test was used to analyze those variables not normally
distributed. Multiple variables were first tested with analysis
of variance and found to be significant, which enabled
individual pairs to be compared. Data are presented as
mean SD. Results were considered significantly different
at P  .05.
RESULTS
Subjects. Of the 41 patients undergoing CEA 28 were
men. Average patient age was 69.6  7.7 years. Eight
patients (19.5%) had diabetes, 32 patients (78%) had hy-
pertension, and 6 patients (14.6%) had had a myocardial
infarction. Eight patients (19.5%) were current smokers,
and 22 patients (53.7%) were ex-smokers. In 25 patients
CEA was performed on the right side, and on the left side in
16 patients. Demographic data for the angioplasty group
were not significantly different. Of the 20 patients under-
going lower limb angioplasty, 14 were male. The average
age of these patients was 70.2 (11.0) years, and the
average weight was 72.8 (11.9) kg. As with the CEA
group, there was a high incidence of comorbidity, with 5 of
20 patients having previously suffered an MI. Thirteen of
the 20 were ex-smokers and 4 continued to smoke. Pre-
senting complaints included rest pain, ulceration, cellulitis
and gangrene (P  .18 for all).
Platelet aggregation. Aggregation to 5 mmol/L of
arachidonic acid in the CEA group is shown in Fig 1. Before
surgery the level of aggregation to arachidonic acid was low
(3.9%  2.2%). Most important, no patient exhibited
greater than 10% aggregation, indicating that there was
adequate inhibition of patient platelets by aspirin before
surgery. There was a small but significant increase in aggre-
gation after induction of anesthesia (10.1% 7.1%), but no
significant increase in aggregation associated with time
point C (incision and soft tissue dissection). However, after
systemic administration of heparin, but before insertion of
the shunt, there was a 10-fold increase in aggregation to
arachidonic acid to 45.1%  29.3% (P  .0001 compared
with baseline and to the previous time point). This level of
response did not increase further after opening of the shunt
(time point E). By 4 hours the response to arachidonic acid
had decreased significantly, but to a level that was still
higher than in the preoperative or pre-heparinization
phases (14.9%  13.2%). By 24 hours the response to
fore t
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further administration of aspirin. At each of these time
points the level of aggregation was significantly higher than
that observed in the preoperative samples (P  .0001). A
similar pattern of aggregation was seen in response to the
lower concentration of arachidonic acid (2.5 mmol/L),
albeit with lower overall levels of aggregation (Fig 2, a).
Spontaneous aggregation showed a similar pattern of
change throughout the procedure, but the levels of aggre-
gation reached were significantly lower that those produced
by either concentrations of arachidonic acid (Fig 2, a) and
could therefore not account for the increased response to
arachidonic acid.
Aggregation in response to an intermediate concentra-
tion of ADP or TRAP also rose by a small amount after
administration of heparin (Fig 2, b). However, these in-
creases did not account for the large increase in response to
arachidonic acid, and could be accounted for by the in-
crease in spontaneous aggregation, because subtraction of
these values removed the increases in the responses to ADP
and TRAP. The changes in platelet aggregation in response
to arachidonic acid (5 mmol/L) were also observed in
patients undergoing peripheral angioplasty (Fig 3). These
patients underwent a closed surgical procedure, with less
tissue damage and without general anaesthesia, but did
receive 2500 to 3500 units of unfractionated heparin. In
the angioplasty group aggregation in response to 5
mmol.l1 of arachidonic acid rose from 5.6%  4.5 %
before the procedure to 33.8%  24.2% after administra-
tion of heparin (P .0001 compared with the preoperative
level; P  .0064 compared with the pre-heparin level).
Significant increases in platelet response to the lower con-
centration of arachidonic acid (2.5 mmol/L) and in spon-
Fig 1. Platelet aggregation in response to arachidonic
tomy at time points A, pre-operative, at admission to hos
C, after skin incision and soft tissue dissection but before
before insertion of shunt; E, 3 minutes after shunt openi
postoperatively; and H, 24 hours postoperatively but betaneous aggregation were also observed in these subjects
after administration of heparin (P .0064 and P .0003,
respectively).
DISCUSSION
Aspirin inhibits platelet COX-1 irreversibly.7,11 It is
therefore reasonable to assume that long-term aspirin ther-
apy, when combined with intraoperative heparin, produces
optimal antithrombotic protection throughout surgery and
during the immediate postoperative period. The findings of
this study appear to contradict this classically held view-
point, but confirm our previous observation that, despite
effective aspirin treatment before surgery, as demonstrated
by the prevention of arachidonic acid–induced platelet
aggregation, the inhibitory effect of aspirin on platelets
apparently can be reversed during carotid surgery.8 This
effect is transient, inasmuch as the platelet response to
arachidonic acid returns to normal over the subsequent 24
hours without further aspirin intake. Furthermore, the
same increase in platelet response to arachidonic acid was
noted in patients undergoing peripheral angioplasty, which
suggests that neither general anaesthesia nor open surgical
procedures are responsible for the change in platelet re-
sponse.
The platelet response to arachidonic acid directly re-
flects the activity of aspirin in platelets. By irreversibly
inhibiting COX-1, aspirin blocks the conversion of arachi-
donic acid to thromboxane A2. Because platelets lack a
nucleus, they cannot synthesise new COX-1; therefore the
effect of aspirin persists for the lifetime of a platelet in the
circulation (normally 8-10 days). Aspirin resistance has
been reported in some patients receiving long-term aspirin
therapy, either from the start of treatment12-16 or develop-
5 mmol/L) in patients undergoing carotid endarterec-
B, After induction of anesthesia but before skin incision;
rinization; D, 3 minutes after heparin was administered,
, at the end of surgery, after flow restoration; G, 4 hours
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resistance occurring in the hours or days after cardiac bypass
surgery.17 This study is, however, unique in having dem-
onstrated transient aspirin resistance that is not only rapidly
induced by the mid-point of surgery but also diminishes
significantly after surgery, without any further aspirin in-
take.
In both the CEA and angioplasty groups, reversal of the
effect of aspirin on the platelet response to arachidonic acid
Fig 2. Platelet aggregation in 41 patients undergoing carotid
endarterectomy. a, Response to arachidonic acid (5 mmol/L, solid
squares; 2.5 mmol/L, solid circles), and spontaneous platelet ag-
gregation (open circles). b, Response to adenosine diphosphate
(0.1 mol/L, solid squares), thrombin-receptor activating peptide
(0.3 mol/L, solid circles), and spontaneous platelet aggregation
(open circles). Samples were analyzed at the following time points:
A, preoperative, at admission to hospital; B, after induction of
anesthesia but before skin incision; C, after skin incision and soft
tissue dissection but before heparinization; D, 3 minutes after
heparin was administered, before insertion of shunt; E, 3 minutes
after shunt opening; F, at the end of surgery, after flow restoration;
G, 4 hours postoperatively; and H, 24 hours postoperatively but
before next dose of aspirin. Data represent mean  SEM.occurred immediately (within 3 minutes) after administra-
tion of unfractionated heparin. Increases in platelet aggre-
gation in response to ADP and TRAP were also observed at
the same time points, but to a smaller degree than the
increases in response to arachidonic acid. This finding can
be accounted for by a similar increase in spontaneous
platelet aggregation, and none of the responses were influ-
enced by potential confounding variables such as gender,
diabetes, or smoking.
The key phase in the operation regarding increased
aggregation to arachidonic acid followed the administra-
tion of heparin. Because samples were taken before carotid
clamping, the observed phenomenon could not be attrib-
uted to clamp-induced ischaemia. Unfractionated heparin
activates platelets and potentiates the effects of physiologic
agonists in vitro and in vivo.18-21 We have previously shown
that the increased response to arachidonic acid seen during
surgery could not be reproduced with comparable levels of
heparin added to blood in vitro.8 Heparin may, however,
have an indirect effect on platelets in vivo. This is substan-
tiated in that the effect on the platelets persisted for longer
than the half-life of heparin. One possible explanation for
the observed phenomenon is supported by research that
has shown that unfractionated heparin releases lipoprotein
lipase from endothelial cells,22 resulting in release of ara-
chidonic acid from plasma lipoproteins.23 This increases
arachidonic acid metabolism by way of the lipoxygenase
pathway,24 resulting in the production of 12-hydroxyeico-
satetra-eonoic acid (12-HETE).25 There are conflicting
data on the role that 12-HETE may have in platelet activa-
tion,26,27 but lipoxygenase metabolism of arachidonic acid
has been implicated as a mechanism for long-term aspirin
resistance.26,28 Ongoing research in this unit is evaluating
Fig 3. Aggregation to arachidonic acid (5 mmol/L) in 18 pa-
tients undergoing angioplasty at the following time points: A,
pre-procedure, at admission to hospital; B, after angiography but
before heparinization; C, 3 minutes after administration of hepa-
rin; D, after angioplasty; and E, 4 hours post procedure. Aggrega-
tion in response to 5 mmol/L of arachidonic acid (closed squares),
2.5 mmol/L of arachidonic acid (closed circles), and spontaneous
platelet aggregation (open circles). Data represent mean  SEM.
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sponsible for the effects observed in this study.
At the therapeutic dose used in this study, aspirin acts
mainly on COX-1, leaving COX-2 unaffected. Unlike
COX-1, COX-2 is rapidly and transiently upregulated in
monocytes and macrophages, and endothelial cells. How-
ever, because in this study platelet aggregation was mea-
sured in platelet-rich plasma (ie, in the absence of other
cells), the effects seen must reflect metabolism of arachi-
donic acid in platelets and preclude involvement of COX-2
from other cells. An alternative mechanism is suggested by
recent observations that link aspirin resistance to the pres-
ence of the inducible enzyme COX-2 in platelets from
patients undergoing coronary artery bypass.17 However,
there is conflicting evidence for platelet COX-2 in the
literature.12,29-31 Added to this, the rapidity of the re-
sponse seen here, together with the reversible nature of the
effect, argues against the likelihood that the effects result
from either the production of new platelets or the switching
on of a gene.
The heparin dose was not weight-adjusted in this study.
We found a positive relationship between patient weight
and the magnitude of the aggregatory response to arachi-
donic acid after administration of heparin (data not
shown), which, although not statistically significant, sug-
gests that heavier patients respond more to the same dose of
heparin than do thin patients. There are 2 possible reasons
for this observation: patient weight affects the effective dose
of aspirin, and larger patients require higher doses of aspirin
to achieve the same effect; or larger patients have a higher
body fat content, which results in a greater effect of heparin
on lipolysis or lipoxygenase activity.
To date, all we have shown is that systemic hepa-
rinization causes an increase in aggregation in response
to arachidonic acid. It therefore remains to be seen
whether this phenomenon is clinically important. The
present study was designed only to explore the timing
and mechanism, and was not powered to study clinical
outcome. Ongoing studies are currently addressing the
pharmacologic causes of this change in aggregation,
together with larger studies of its potential clinical rele-
vance (perioperative morbidity, mortality, rate of post-
operative embolization).
A control group not receiving aspirin was not in-
cluded in the present study. The primary observation is
that platelets that have been previously inhibited by
aspirin rapidly become sensitive to arachidonic acid after
heparin administration. Because patients not taking as-
pirin would have a normal response to arachidonic acid,
we would not expect to see the former effect. Although
heparin can cause an increase in spontaneous platelet
aggregation and enhance the response to agonists such as
ADP in healthy subjects and patients,19 the effect is small
compared with the dramatic effect on the efficacy of
aspirin, reported here for the first time.
In conclusion, every cardiovascular intervention in-
volves a degree of risk for early thromboembolic compli-
cations, despite the use of heparin and anti-platelet ther-apy. While some of these complications may be related to
inadvertent technical error, transient but diminished ef-
ficacy of aspirin could explain why a small number of
patients are at increased risk for thromboembolic com-
plications (eg, stroke, myocardial infarction) in the im-
mediate postoperative period after cardiovascular proce-
dures.
REFERENCES
1. Ferguson GG, Eliasziw M, Barr HW, Clagett GP, Barnes RW, Wallace
MC, et al. The North American Symptomatic Carotid Endarterectomy
Trial. Surgical results in 1415 patients. Stroke 1999;30:1751-8.
2. Rothwell PM, Gutnikov SA, Warlow CP. Reanalysis of the final results
of the European Carotid Surgery Trial. Stroke 2003;34:514-23.
3. Naylor AR, Hayes PD, Allroggen H, Lennard N, Gaunt ME, Thomp-
son MM, et al. Reducing the risk of carotid surgery: a 7-year audit of the
role of monitoring and quality control assessment. J Vasc Surg 2000;
32:750-9.
4. Gaunt ME, Smith JL, Ratliff DA, Bell PR, Naylor AR. A comparison of
quality control methods applied to carotid endarterectomy. Eur J Vasc
Endovasc Surg 1996;11:4-11.
5. Hobson RW, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne
JB, et al. Efficacy of carotid endarterectomy for asymptomatic carotid
stenosis. The Veterans Affairs Cooperative Study Group. N Engl J Med
1993;328:221-7.
6. MRC European Carotid Surgery Trial. Interim results for symptomatic
patients with severe (70-99%) or with mild (0-29%) carotid stenosis.
European Carotid Surgery Trialists’ Collaborative Group. Lancet 1991;
337:1235-43.
7. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin syn-
thase by aspirin. Proc Natl Acad Sci U S A 1975;72:3073-6.
8. Payne DA, Jones CI, Webster SE, Hayes PD, Bell PRF, Naylor AR, et al.
Platelet inhibition by aspirin is diminished in patients during carotid
surgery: a form of transient aspirin resistance? Thromb Haemost 2004;
92:94-101.
9. Lennard N, Smith J, Dumville J, Abbott R, Evans DH, London NJ, et
al. Prevention of postoperative thrombotic stroke after carotid endar-
terectomy: the role of transcranial Doppler ultrasound. J Vasc Surg
1997;26:579-84.
10. Born GVR. Quantitative investigations into the aggregation of blood
platelets. J Physiol 1962;162:167-71.
11. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al.
Platelet-active drugs: the relationships among dose, effectiveness and
side effects. Chest 2001;119 Suppl 1:S39-63.
12. Altman R, Luciardi HL, Muntaner J, Herrera RN. The antithrombotic
profile of aspirin: aspirin resistance, or simply failure? Thromb J 2004;
2:1-8.
13. Pappas JM, Westengard JC, Bull BS. Population variability in the effect
of aspirin on platelet function: implications for clinical trials and ther-
apy. Arch Pathol Lab Med 1994;118:801-4.
14. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi O, Yusuf S. Aspirin-
resistant thromboxane biosynthesis and the risk of myocardial infarc-
tion, stroke, or cardiovascular death in patients at high risk for cardio-
vascular events. Circulation 2002;105:1650-5.
15. Gum PA, Kotte-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks
L, et al. Profile and prevalence of aspirin resistance in patients with
cardiovascular disease. Am J Cardiol 2001;88:230-5.
16. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice
KL, et al. Development of aspirin resistance in persons with previous
ischaemic stroke. Stroke 1994;25:2331-6.
17. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, et al.
Functional and biochemical evaluation of platelet aspirin resistance after
coronary artery bypass surgery. Circulation 2003;108:542-7.
18. Landolfi R, De Candia E, Rocca B, Ciabattoni G, Antinori A, Masetti R,
et al. Effects of unfractionated and low molecular weight heparins on
platelet thromboxane biosynthesis in vivo.” Thromb Haemost 1994;
72:942-6.
JOURNAL OF VASCULAR SURGERY
September 2004468 Webster et al19. Knight CJ, Panesar M, Patrineli A, Chronos N, Wright C, Clarke D, et
al. Increased platelet responsiveness following coronary stenting: hepa-
rin as a possible aetiological factor in stent thrombosis. Eur Heart J
1998;19:1239-48.
20. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at
therapeutic concentrations and comparisons with a low-molecular-
weight heparin and with a direct thrombin inhibitor. Circulation 1998;
97:251-6.
21. Berglund U, Wallentin L. Influence on platelet function by heparin in
men with unstable coronary artery disease. Thromb Haemost 1991;66:
648-51.
22. Olivecrona T, Bengtsson-Olivecrona G, Ostergaard P, Liu G, Chevreuil
O, Hultin M. New aspects on heparin and lipoprotein metabolism.
Haemostasis 1993;23:150-60.
23. Muriithi EW, Belcher PR, Day SP, Chaudhry MA, Caslake MJ, Wheat-
ley DJ. Lipolysis generates platelet dysfunction after in vivo heparin
administration. Clin Sci 2002;103:433-40.
24. Melin T, Qi C, Bengtsson-Olivecrona G, Akesson B, Nilsson A. Hy-
drolysis of chylomicron polyenoic fatty acid esters with lipoprotein
lipase and hepatic lipase. Biochim Biophys Acta 1991;1075:259-66.
25. Sutherland M, Shankaranarayanan P, Schewe T, Nigam S. Evidence for
the presence of phospholipid hydroperoxide glutathione peroxidase in
human platelets: implications for its involvement in the regulatorynetwork of the 12-lipoxygenase pathway of arachidonic acid
metabolism. Biochem J 2001;353:91-100.
26. Buchanan MR, Butt RW, Hirsh J, Markham BA, Nazir DJ. Role of
lipoxygenase metabolism in platelet function: effect of aspirin and
salicylate. Prostaglandins Leukot Essent Fatty Acids 1986;21:157-68.
27. Morita I, Murota SI. Role of 12-lipoxygenase products of arachidonic
acid on platelet aggregation. Adv Prostaglandin Thromboxane Leukot
Res 1987;17:219-23.
28. Johnson EN, Brass LF, Funk CD. Increased platelet sensitivity to ADP
in mice lacking platelet-type 12 lipoxygenase. Proc Natl Acad Sci U S A
1998;95:3100-5.
29. Reiter R, Resc U, Sinzinger H. Do human platelets express COX-2?
Prostaglandins Leukot Essent Fatty Acids 2001;64:299-305.
30. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cycloox-
ygenase-2 in human platelets as a possible factor in aspirin resistance.
Lancet 1999;353:900.
31. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti
L, et al. Cyclooxygenase-2 expression is induced during human
megakaryopoiesis and characterizes newly formed platelets. Proc Natl
Acad Sci U S A 2002;99:7634-9.
Submitted Apr 30, 2004; accepted Jun 21, 2004.PREVIEW UPCOMING ARTICLES ON THE WEB
Articles that have been accepted for publication and copyedited can often be read on the Journal Web site 1 or 2
months before publication in print. The full text of the article with all figures, references, and reference links to
PubMed are available. The articles can be printed in their final format using the PDF link.
